Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care Inc.

Bernstein analyst Lee Hambright maintained a Hold rating on Tandem Diabetes Care yesterday and set a price target of $18.00. Hambright covers the H...

Bernstein Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)

Barclays analyst Matt Miksic maintained a Buy rating on Tandem Diabetes Care today and set a price target of $55.00. Miksic covers the Healthcare s...

Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)

Tandem Diabetes Care (($TNDM)) has held its Q3 earnings call. Read on for the main highlights of the call. Tandem Diabetes Care’s recent earnings c...

Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report), Lemai...

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Lemaitre Vascular (LMAT) and Shattuck Labs (STTK)

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Tandem Diabetes Care, with a price target of $16.00. Bl...

Current Quarter	$-0.06	Next Quarter	$-0.44
Current Year	$-2.35	Next Year	$-0.96
QoQ Growth	-633.3%	YoY Growth	+59.1%
3Y EPS CAGR	-99.0%	Target Price	$21.14
Consensus	Buy	Upside	-0.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TNDM	$21.28	+9.13%	3.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TNDM	$21.28	+9.1%	3.27M
3
4
5
6

TNDM

TNDM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Tandem Diabetes Care Inc. Data in Excel

Get Tandem Diabetes Care Inc. Data in Excel